中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
柔红酮 | (+)-Daunomycinone | 21794-55-8 | C21H18O8 | 398.369 |
(7S,9S)-9-乙酰基-7-[(4S,5S,6S)-4-氨基-5-羟基-6-甲基四氢吡喃-2-基]氧基-4,6,9,11-四羟基-8,10-二氢-7H-并四苯-5,12-二酮盐酸盐 | carminomycin | 50935-04-1 | C26H27NO10 | 513.501 |
道诺霉素 | DNR | 20830-81-3 | C27H29NO10 | 527.528 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(7S,9S)9-乙酰基-7,8,9,10-四氢-6,7,9,11-四羟基-5,12-并四苯二酮 | (7S,9S)-idarubicinone | 60660-75-5 | C20H16O7 | 368.343 |
—— | (7S,9S)-4,6,7,9,11-pentahydroxy-9-(1-hydroxyethyl)-8,10-dihydro-7H-tetracene-5,12-dione | 62152-30-1 | C20H18O8 | 386.358 |
—— | (8R)-8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-5,12-naphthacenedione | 63229-48-1 | C20H16O6 | 352.343 |
—— | (7S,9S)-4,6,7,9,11-pentahydroxy-9-(2-methyl-1,3-dioxolan-2-yl)-8,10-dihydro-7H-tetracene-5,12-dione | 75075-21-7 | C22H20O9 | 428.395 |
—— | (7S,9S)-6,7,9,11-tetrahydroxy-9-(2-methyl-1,3-dioxolan-2-yl)-8,10-dihydro-7H-tetracene-5,12-dione | 84700-18-5 | C22H20O8 | 412.396 |
—— | 7-O-(4-epi-α-L-vancosaminyl)-carminomycinone | 135095-15-7 | C27H29NO10 | 527.528 |
—— | 4-Demethyl-4-(trifluoromethanesulfonyl)-13-dioxolanyldaunomycinone | 128065-73-6 | C23H19F3O11S | 560.458 |
—— | 12-deoxycarminomycinone | —— | C20H16O7 | 368.343 |
Hydrogenation of the anthracyclines daunorubicin (1) and doxorubicin (2) gave selective deoxygenation at position 5. Hydride reduction of (1) and (2) gave complementary regiocontrol, leading to 12-deoxygenation or 5,12- bisdeoxygenation. This chemistry allows retention of the 7-glycoside and the side-chain carbonyl groups. It has led to new anthracycline families possessing all of the stereochemical and most of the spatial characteristics of the parent compounds (1) and (2). These are typified by 5-deoxy (12), (15); 12-deoxy (22), (23); 5,12-bisdeoxy (34), (35); and 4,5,12-trisdeoxy systems (36). All possess high anticancer activity.